AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22230919 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-threshold cutoffs for saliva osmolality
Number of subjects: 12
Study 22230919 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-threshold detection technique for saliva osmolality
Number of subjects: 12
Study 19464026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 15 microg
Number of subjects: 12
Study 19464026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg
Number of subjects: 12
Study 19464026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19464026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (both doses)
Number of subjects: 12
Study 19464026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 12
Study 17535711 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated allograft saphenous vein (group A)
Number of subjects: 34
Study 17535711 — intervention group
Group type: COMPARATOR
Intervention: Fresh allograft (group B)
Number of subjects: 34
Study 17535711 — intervention group
Group type: COMPARATOR
Intervention: Fresh self-graft (group C)
Number of subjects: 34
Study 16075574 — intervention group
Group type: EXPERIMENTAL
Intervention: Child health and nutrition interventions, specific details not available.
Number of subjects: 0
Study 16075574 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 11801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost once daily
Number of subjects: 32
Study 11801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone twice daily
Number of subjects: 32
Study 11801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost added to unoprostone
Number of subjects: 32
Study 11801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone added to latanoprost
Number of subjects: 32
Study 9695964 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha, 3 x 10(6) units/m2 subcutaneously three times weekly until relapse
Number of subjects: 85
Study 9695964 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 85
Study 9695964 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 85
Study 9695964 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 7986464 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily (n = 77)
Number of subjects: 154
Study 7986464 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 50 mg twice daily (n = 77)
Number of subjects: 154
Study 2723246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl intravenously (3 micrograms/kg) prior to surgery
Number of subjects: 0
Study 2723246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30397904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at P6 plus antiemetics (n = 86)
Number of subjects: 161
Study 30397904 — intervention group
Group type: COMPARATOR
Intervention: Anti-emetics only (n = 75)
Number of subjects: 161
Study 28237958 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐intervention Tabac Info Service (e‐TIS)
Number of subjects: 3000
Study 28237958 — intervention group
Group type: COMPARATOR
Intervention: Current practices (Control)
Number of subjects: 3000
Study 25817374 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 703
Study 25817374 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 703
Study 22836633 — intervention group
Group type: COMPARATOR
Intervention: Normal laboratory condition (N)
Number of subjects: 12
Study 22836633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold field condition (C)
Number of subjects: 12
Study 21146770 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting The Conversation (STC) dietary assessment tool
Number of subjects: 463
Study 21146770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 463
Study 19917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 235
Study 19917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 235
Study 19917166 — intervention group
Group type: EXPERIMENTAL
Intervention: High homocysteine levels
Number of subjects: 235
Study 16396765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone combined with once daily cytarabine
Number of subjects: 165
Study 14700448 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) strategies, including maximally tolerated doses, switching medications, combining dissimilar medications, and combining psychotherapy with medication.
Number of subjects: 0
Study 14700448 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (current first-line standard of care)
Number of subjects: 0
Study 12374491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12374491 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 300 mg/d
Number of subjects: 80
Study 12374491 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 600 mg/d
Number of subjects: 80
Study 12374491 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 1200 mg/d
Number of subjects: 80
Study 9879213 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanora
Number of subjects: 254
Study 9879213 — intervention group
Group type: COMPARATOR
Intervention: Conventional (panoramic + intra-oral radiographs)
Number of subjects: 254
Study 9879213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 254
Study 8026236 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-ml oral sodium phosphate preparation
Number of subjects: 450
Study 8026236 — intervention group
Group type: COMPARATOR
Intervention: 4-liter polyethylene glycol solution
Number of subjects: 450
Study 8026236 — intervention group
Group type: COMPARATOR
Intervention: sulfate-free 4-liter polyethylene glycol solution
Number of subjects: 450
Study 2607910 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 3 ug/kg
Number of subjects: 12
Study 2607910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 ug/kg plus aminophylline 3 mg/kg iv
Number of subjects: 12
Study 31876900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly or every 2 weeks
Number of subjects: 422
Study 31876900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks
Number of subjects: 422
Study 31876900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 8 weeks
Number of subjects: 422
Study 31876900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 31288352 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2-mm clear corneal incision
Number of subjects: 131
Study 31288352 — intervention group
Group type: COMPARATOR
Intervention: 3.0-mm clear corneal incision
Number of subjects: 131
Study 28343413 — intervention group
Group type: EXPERIMENTAL
Intervention: Corner store intervention
Number of subjects: 9347
Study 28343413 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholesaler intervention
Number of subjects: 9347
Study 26061267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and midazolam
Number of subjects: 37
Study 26061267 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation with midazolam and pethidine
Number of subjects: 37
Study 23852679 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV seronegative younger participants
Number of subjects: 107
Study 23852679 — intervention group
Group type: COMPARATOR
Intervention: CMV seropositive younger participants
Number of subjects: 107
Study 23852679 — intervention group
Group type: COMPARATOR
Intervention: CMV serostatus among older group
Number of subjects: 107
Study 20490797 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg/m²/day for five consecutive days per week for 1 year)
Number of subjects: 610
Study 20490797 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 610
Study 18710700 — intervention group
Group type: EXPERIMENTAL
Intervention: Children providing explanations for contamination
Number of subjects: 60
Study 18710700 — intervention group
Group type: COMPARATOR
Intervention: Children making predictions for contamination
Number of subjects: 60
Study 18710700 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to varying desirability of contaminated substance (Study 2)
Number of subjects: 60
Study 17077073 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/d for 7 days)
Number of subjects: 34
Study 17077073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 17077073 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 34
Study 14656658 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral (A‐L) THA
Number of subjects: 29
Study 14656658 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral (P‐L) THA
Number of subjects: 29
Study 14656658 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied control group
Number of subjects: 29
Study 14656658 — intervention group
Group type: EXPERIMENTAL
Intervention: Total THA patients (A‐L and P‐L combined)
Number of subjects: 29
Study 11500188 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (lisinopril)
Number of subjects: 39
Study 11500188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates (fenofibrate)
Number of subjects: 39
Study 11500188 — intervention group
Group type: COMPARATOR
Intervention: High fat meal
Number of subjects: 39
Study 11500188 — intervention group
Group type: COMPARATOR
Intervention: Low fat meal
Number of subjects: 39
Study 9228228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg or 20 mg
Number of subjects: 30
Study 9228228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8131386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime BPD group (n = 13)
Number of subjects: 39
Study 8131386 — intervention group
Group type: COMPARATOR
Intervention: Active BPD group (n = 26)
Number of subjects: 39
Study 28068656 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 0.50 (oxygen-enriched air)
Number of subjects: 32
Study 28068656 — intervention group
Group type: COMPARATOR
Intervention: FiO2 0.21 (ambient air)
Number of subjects: 32
Study 26063762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing (assessment of BP and cardiovascular risk, education on hypertension, prescribing of antihypertensive medications, laboratory monitoring, and monthly follow-up visits for 6 months)
Number of subjects: 248
Study 26063762 — intervention group
Group type: COMPARATOR
Intervention: Usual care from pharmacist and physician (wallet card for BP recording, written hypertension information)
Number of subjects: 248
Study 26063762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing
Number of subjects: 248
Study 23607714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064 nm Q-switched Nd: YAG laser (1064 QSNY) for 10 sessions at 2-week intervals
Number of subjects: 26
Study 23607714 — intervention group
Group type: COMPARATOR
Intervention: 1550 nm fractional photothermolysis (NFP) for five sessions at 4-week intervals
Number of subjects: 26
Study 21929518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 80
Study 21929518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 80
Study 21929518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 80
Study 21929518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18583285 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 300 mg/day
Number of subjects: 60
Study 18583285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg/day + Clopidogrel 75 mg/day
Number of subjects: 60
Study 16567982 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 9VPCV
Number of subjects: 0
Study 16567982 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of 9VPCV
Number of subjects: 0
Study 14576714 — intervention group
Group type: EXPERIMENTAL
Intervention: Video lessons (self-administered, video-lesson packets)
Number of subjects: 93
Study 14576714 — intervention group
Group type: COMPARATOR
Intervention: Traditional lessons (face-to-face sessions)
Number of subjects: 93
Study 14576714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Video Group and Traditional Group)
Number of subjects: 93
Study 11089626 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 5507
Study 11089626 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepubertal circumcision
Number of subjects: 5507
Study 11089626 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision in HIV-positive men with viral loads <50,000 copies/ml
Number of subjects: 5507
Study 8721244 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% Sumithrine
Number of subjects: 4
Study 8721244 — intervention group
Group type: COMPARATOR
Intervention: 1% Lindane
Number of subjects: 4
Study 1333181 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg subcutaneous sumatriptan
Number of subjects: 242
Study 1333181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg subcutaneous sumatriptan
Number of subjects: 242
Study 1333181 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg subcutaneous sumatriptan
Number of subjects: 242
Study 1333181 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg subcutaneous sumatriptan
Number of subjects: 242
Study 1333181 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 242
Study 1333181 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg subcutaneous sumatriptan
Number of subjects: 242
Study 1333181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 3881206 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol, 1 mg iv, followed by 1 mg doses at 20-min intervals
Number of subjects: 160
Study 3881206 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 3881206 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 160
Study 3881206 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol for paroxysmal supraventricular tachycardia
Number of subjects: 160
Study 3881206 — intervention group
Group type: COMPARATOR
Intervention: placebo for paroxysmal supraventricular tachycardia
Number of subjects: 160
Study 3881206 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol for atrial fibrillation
Number of subjects: 160
Study 3881206 — intervention group
Group type: COMPARATOR
Intervention: placebo for atrial fibrillation
Number of subjects: 160
Study 3881206 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol for atrial flutter
Number of subjects: 160
Study 3881206 — intervention group
Group type: COMPARATOR
Intervention: placebo for atrial flutter
Number of subjects: 160
Study 30329105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 172
Study 29453622 — intervention group
Group type: EXPERIMENTAL
Intervention: OA intervention group (12-month phone-based patient behavioral protocol including weight management, physical activity, and cognitive-behavioral pain management)
Number of subjects: 300
Study 29453622 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 300
Study 26663636 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulating the rank position of tooth-brushing duration in Study 2
Number of subjects: 0
Study 26663636 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages relating to rank positions of tooth-brushing durations in Study 3
Number of subjects: 0
Study 26663636 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported attitudes, cognitions, and behavior towards tooth-brushing duration in Studies 1 and 2
Number of subjects: 0
Study 24655473 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Number of subjects: 0
Study 22735462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 62
Study 22735462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg
Number of subjects: 62
Study 22735462 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 62
Study 22735462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20445768 — intervention group
Group type: EXPERIMENTAL
Intervention: WALC‐S intervention
Number of subjects: 97
Study 20445768 — intervention group
Group type: COMPARATOR
Intervention: Time-and-attention control (TAC)
Number of subjects: 97
Study 17660871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 17660871 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 0
Study 17660871 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 17660871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 16309053 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling group (acupuncture at local acupoints and deeply needling at local acupoints to nerve stem for 3 courses)
Number of subjects: 90
Study 16309053 — intervention group
Group type: COMPARATOR
Intervention: Routine needling group (shallow acupuncture at local acupoints and distal acupoints along the Hand and Foot‐Yangming Channels)
Number of subjects: 90
Study 11923548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 750 microg bd
Number of subjects: 35
Study 11923548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9797055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush
Number of subjects: 31
Study 9797055 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 31
Study 8596749 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO therapy for 12 months
Number of subjects: 20
Study 8596749 — intervention group
Group type: COMPARATOR
Intervention: No treatment (No-EPO group)
Number of subjects: 20
Study 2650482 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-flow Doppler
Number of subjects: 74
Study 2650482 — intervention group
Group type: COMPARATOR
Intervention: Conventional duplex scanning
Number of subjects: 74
Study 786961 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (400 mcg/day)
Number of subjects: 19
Study 786961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31015318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraincisional ropivacaine (0.2%)
Number of subjects: 191
Study 31015318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (0.2%)
Number of subjects: 191
Study 31015318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intraincisional and intraperitoneal ropivacaine (0.2%)
Number of subjects: 191
Study 27998692 — intervention group
Group type: EXPERIMENTAL
Intervention: Squill Oxymel (10ml syrup, 2 times a day)
Number of subjects: 60
Study 27998692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple oxymel (10ml syrup, 2 times a day)
Number of subjects: 60
Study 27998692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25787895 — intervention group
Group type: EXPERIMENTAL
Intervention: DC loaded with recombinant Prostate Specific Membrane Antigen (rPSMA) and recombinant Survivin (rSurvivin) peptides administered as a subcutaneous (s.c.) injection (5×10(6) cells)
Number of subjects: 21
Study 25787895 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m(2) intravenous (i.v.)) and prednisone (5 mg, bis in die (b.i.d.))
Number of subjects: 21
Study 23676938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating behavior intervention
Number of subjects: 0
Study 23676938 — intervention group
Group type: COMPARATOR
Intervention: Conventional health care
Number of subjects: 0
Study 21827648 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walks of 30 minutes a day, 5 days a week as part of daily nursing care.
Number of subjects: 0
Study 21827648 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activities (tea or other activities) three times a week.
Number of subjects: 0
Study 19413409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking satisfaction
Number of subjects: 394
Study 19413409 — intervention group
Group type: COMPARATOR
Intervention: Patch treatment for smoking cessation
Number of subjects: 394
Study 19413409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking in positive moods
Number of subjects: 394
Study 19413409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of craving prior to smoking
Number of subjects: 394
Study 17270294 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian subjects
Number of subjects: 248
Study 14517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg
Number of subjects: 36
Study 14517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 36
Study 14517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 36
Study 14517190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11188492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily positive and negative affect
Number of subjects: 46
Study 11188492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily nonwork events (positive and negative)
Number of subjects: 46
Study 11188492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily work events (positive and negative)
Number of subjects: 46
Study 11188492 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative work events
Number of subjects: 46
Study 11188492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime symptoms of alcohol dependence and treatment condition
Number of subjects: 46
Study 9195351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg i.v. propofol bolus followed by a continuous 0.5 mg/kg/hr infusion
Number of subjects: 40
Study 9195351 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose solution
Number of subjects: 40